In face of the rising COVID cases in the country, Indian pharmaceutical company Bajaj Healthcare has announced the launch of its anti-viral drug Favipiravir, under the brand name Favijaj for the treatment of ‘mild to moderate COVID-19 patients’.
This comes as the country is in the midst of a second wave of the coronavirus pandemic that has led to severe shortages of medicines and healthcare facilities.
Favipiravir is an antiviral drug used for the treatment of patients suffering from the influenza virus and has been proven effective in treating COVID-19 patients.
The drug was launched after receiving the necessary manufacturing and marketing approvals from India’s drug regulator and the company has also received permissions to supply ‘Favijaj’ (Favipiravir) to the domestic as well as overseas markets.
Bajaj Healthcare Limited has developed the active pharmaceutical ingredient (API) and the formulation for Favipiravir through its in-house Research and Development (R&D) team.
